Evidence map›Paper›PMID 40931236›Full record

ReviewVirchows Archiv : an international journal of pathology2026

MiNEN, amphicrine carcinomas, and conventional carcinomas with neuroendocrine differentiation: diagnostic criteria, open questions, and future perspectives.

Moritz Jesinghaus, Maxime Philipp Schmitt, Sebastian Foersch, Björn Konukiewitz

Abstract readReview
In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Moritz JesinghausInstitute of Pathology, Philipps-Universität Marburg, Marburg, Germany. moritz.jesinghaus@uni-marburg.de.ORCID http://orcid.org/0000-0002-0018-5661
Maxime Philipp SchmittInstitute of Pathology, Philipps-Universität Marburg, Marburg, Germany.
Sebastian FoerschInstitute of Pathology, University Medical Center Mainz, Mainz, Germany.
Björn KonukiewitzInstitute of Pathology, University Hospital Schleswig-Holstein, Kiel, Germany.

Funding

BMBF 01KD2215CBMBF 01KD2420EBMBF DECIPHER-MBMBF SWAGDeutsche Forschungsgemeinschaft 504101714Deutsche Krebshilfe 70115166Deutsche Krebshilfe Project-ID 360372040
6 · The paper itself

Abstract

Mixed neuroendocrine and non-neuroendocrine neoplasms (MiNEN) represent a heterogeneous group of bidirectionally differentiated epithelial malignancies that are, in most cases, highly aggressive. They are defined by the presence of morphologically distinct, yet clonally related, neuroendocrine and non-neuroendocrine components, each comprising at least 30% of the tumor mass according to current guidelines. Tumors that fall within the differential diagnostic spectrum of MiNEN include amphicrine carcinomas-characterized by the co-expression of neuroendocrine and non-neuroendocrine features within the same tumor cell-as well as conventional carcinomas that lack neuroendocrine morphology but exhibit immunohistochemical expression of neuroendocrine markers. However, these entities do not fulfill the current diagnostic criteria for MiNEN. In this review, we aim to outline the current diagnostic framework for MiNEN and examine the conceptual and classification boundaries of amphicrine carcinomas and conventional carcinomas with aberrant neuroendocrine marker expression in relation to what is presently defined as a MiNEN. In addition, we highlight key unresolved questions that should be addressed in future guidelines to streamline the diagnostic process and improve consistency. Finally, we provide an outlook on emerging technologies and future perspectives that may further refine the classification and clinical management of these complex neoplasms.

Indexed as

CarcinomaCarcinoma, NeuroendocrineNeoplasms, Complex and MixedNeuroendocrine TumorsBiomarkers, TumorDiagnosis, DifferentialHumansBiomarkers, TumorAmphicrine carcinomaMANECMiNENNeuroendocrine carcinomaNeuroendocrine neoplasmNeuroendocrine tumor

Identifiers

PMID40931236
PMCPMC12876519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.